What is the relationship between sclerostin and cardiovascular events in hemodialysis patients?

Yu Zhaoa Department of Medicine, Northwest University for Nationalities, Lanzhou, PR China

Wenyun Wangb Department of Pediatric Surgery, Second Hospital of Lanzhou University, Lanzhou, PR China

Zhilong Dongc Department of Urology, Second Hospital of Lanzhou University, Lanzhou, PR ChinaCorrespondence[email protected]

References

Zou Y, Yang M, Wang J, et al. Association of sclerostin with cardiovascular events and mortality in dialysis patients. Ren Fail. 2020;42(1):282–288.
PubMed Web of Science ®Google Scholar
Gonçalves FL, Elias RM, dos Reis LM, et al. Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrol. 2014;15(1):190.
PubMedGoogle Scholar
Jean G, Chazot C, Bresson E, et al. High serum sclerostin levels are associated with a better outcome in haemodialysis patients. Nephron. 2016;132(3):181–190.
PubMed Web of Science ®Google Scholar
Drechsler C, Evenepoel P, Vervloet MG, et al. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant. 2015;30(2):288–293.
PubMed Web of Science ®Google Scholar
Kalousová M, Dusilová-Sulková S, Kuběna AA, et al. Sclerostin levels predict cardiovascular mortality in long-term hemodialysis patients: a prospective observational cohort study. Physiol Res. 2019;68(4):547–558.
PubMed Web of Science ®Google Scholar